• Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month
Page
  1. 1
    1
  2. 2
    2
  3. 3
    3
  4. 4
    4
  5. 5
    5
  6. 6
    6
  7. 7
    7
  8. 8
    8
  9. 9
    9
  10. 10
    10
  11. 11
    11
  12. 12
    12

GSK case study

Extracts from this document...

Introduction

Case Study on: GlaxoSmithKline Case OBJECTIVE: "GSK" TO SUPPLY ANTIRETROVIRALS AND ANTI-MALARIALS AT SUSTAINABLE PREFERENTIAL PRICES FOR ELIGIBLE CUSTOMERS IN THE LEAST DEVELOPED COUNTRIES AND ALL SUB-SAHARAN AFRICAN COUNTRIES. Eligible customers include the public sector, not-for-profit NGOs, aid agencies, UN agencies and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. Additionally, because of the gravity of the situation in sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics are also eligible. MADE BY: JIGAR.R.RAJPURA X-01824544 Sustainable Preferential Pricing Arrangements GlaxoSmithKline has offered preferential pricing for our HIV/AIDS medicines since 1997. They placed a high priority on their prices being sustainable. This means setting prices at levels that meet their costs, thereby ensuring they can sustain supply of these high-quality products for as long as they are needed. The Promise In 'Facing the Challenge' it is promised to: � extend preferential pricing to more products, countries and customers; � supply antiretrovirals and anti-malarials at preferential prices to public sector customers and not-for-profit organisations in 63 countries - all the Least Developed Countries of the world and all of sub-Saharan Africa; � supply ARV therapy at preferential prices to employers in sub-Saharan Africa who provide HIV/AIDS care and treatment directly to their staff through their own workplace clinics; � make thier ARVs and anti-malarials available at preferential prices to international purchase funds; � set up pilot projects with non-governmental organisations (NGOs) ...read more.

Middle

GRAPH A: SUPPLY ARRANGEMENTS BY CUSTOMER TYPE GRAPH B: CUMULATIVE SHIPMENTS OF COMBIVIR TABLETS 100 80 60 40 Employers Public Hospitals NGOs Govt Non AAI AAI 8000000 7000000 6000000 5000000 4000000 3000000 Combivir tablets 20 0 Q4 2000 Q1 2001 Q2 2001 Q3 2001 Q4 2001 Q1 2002 Q2 2002 2000000 1000000 0 Q1 2001 Q2 2001 Q3 2001 Q4 2001 Q1 2002 Q2 2002 Research and Development Continued investment in research into diseases that affect the developing world is essential to long-term improvement in the health of people in these regions, not least because of challenges such as development of drug resistance to current treatments and poor patient adherence. For neglected communicable diseases, GlaxoSmithKline already has one of the most extensive portfolios of novel products and development projects in the industry. We are the only company currently involved in R&D for both the prevention and treatment of all three top priority diseases of the World Health Organization: malaria, tuberculosis and HIV/AIDS. And we currently have between 20 and 30 R&D projects and programmes of relevance to the developing world, of which ten are aimed at producing medicines primarily for developing countries.GSK frequently pursues a public/private partnership (PPP) model for R&D into diseases of the developing world. ...read more.

Conclusion

1987 - Burroughs Wellcome (a GSK legacy company) introduces the first antiretroviral (ARV), zidovudine (AZT). 1992 - GSK establishes Positive Action. 1994 - US Food and Drug Administration (FDA) approves GSK's Retrovir for the prevention of mother-to-child transmission of HIV. 1996 - Combination therapy involving a 'cocktail' of drugs promises longer AIDS-free survival. 1997 - FDA approves GSK's Combivir, the first product to combine two ARVs in a single tablet. GSK is the first company to sell an ARV therapy at highly discounted prices to sub-Saharan Africa. 2000 - FDA approves GSK's Trizivir, the first combination of three ARVs in a single tablet. 2001 - 47 million people are infected with HIV, 26 million of these live in Africa. GSK grants its first voluntary licence for the manufacture of generic versions of our ARVs in South Africa. 2007 - HIV infection is no longer a death sentence for people in the developed world, but the epidemic is increasing in Africa and Asia.GSK remains to work efficiently in the tackling of AIDS. REFRENCES: 1) http://www.gsk.com/responsibility/cr-review-2006/case-studies/aids.htm 2) In May 2002 we published 'Performance with Integrity - a Review of GlaxoSmithKline's Commitment to Society and the Environment'. This publication expands on the information on medicines for the developing world in the review which can be found at: www.gsk.com/ser/2001/ser01/index-still.html 3) http://jama.ama-assn.org/issues/v286n15/rfull/jsc10222.html 4) http://mosquito.who.int 5) http://www.malariavaccine.org/ 6) http://www.ehealthcube.co.uk/community/downloads/facing_the_challenge_one_year_on.pdf ?? ?? ?? ?? 1 | Page ...read more.

The above preview is unformatted text

This student written piece of work is one of many that can be found in our AS and A Level Healthcare section.

Found what you're looking for?

  • Start learning 29% faster today
  • 150,000+ documents available
  • Just £6.99 a month

Not the one? Search for your essay title...
  • Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

See related essaysSee related essays

Related AS and A Level Healthcare essays

  1. Marked by a teacher

    Investigating Diseases. I will be looking at and comparing communicable and non communicable diseases. ...

    4 star(s)

    Some have a flu-like illness, called HIV sero-conversion syndrome, a month or two after exposure to the virus. This illness may cause a variety of symptoms. I will now explain a bit about how each symptom can affect the persons P.I.E.S life.

  2. Communicable and Non-Communicable Disease: Tuberculosis and Cystic Fibrosis

    an individual is born with cystic fibrosis, but changes to the environment of an individual who is already suffering from the disease (such as minimising exposure to second-hand smoke) can improve his/her condition.49 The average lifespan of a person affected with cystic fibrosis is twenty-eight to thirty years.50 It is

  1. Research In Clinical Practise

    the use of a RCT, and whether it was achieved - the abstract states the ulcers of patients in the clinic group tended to heal sooner than those in the control group. Likewise, Simon et al do not clearly identify the research problem within their abstract.

  2. Complementary Therapies

    that enables you to have the time and space to look at the different aspects of your life The number of times you meet with the counsellor will be something that is agreed at the first meeting, and reviewed regularly as you make progress.

  1. Unit 4-Human lifespan development

    Children carefully watch the behavior of their caretakers, other adults, and older children. If they see Uncle Dan being helpful to strangers, they'll be more likely to be helpful to others as well. Parenting practices and daily discipline have a huge effect on a child's developing sense of morality.

  2. Child development - patterns of development. To increase my awareness and knowledge of ...

    The first pattern of physical development that I am going to focus on is weight. Infant Weight of Marie General weight Newborn 4 pounds 5.25 oz. 7.16 pounds 3months 7 pounds 12.5 pounds 6months 10 pounds 16.53 pounds 9months 13 pounds 19.62 pounds 12months 16 pounds 21.76 pounds Toddler Weight

  • Over 160,000 pieces
    of student written work
  • Annotated by
    experienced teachers
  • Ideas and feedback to
    improve your own work